Bioxytran Q2 10-Q: Going Concern, $2.69M Loss, CEO Grant
BIXT is trading near its 52-week low of $0.021 (0.5% above the low).
Summary
Bioxytran's Q2 2026 10-Q reiterates a going concern warning with cash only through September 2026, reports a $2.69M net loss, and discloses a $1.28M CEO performance grant and material weakness in internal controls.
Key Events · Earnings and Guidance · BIXT
-
Going Concern Warning
Cash of $177,384 at June 30, 2026, with management stating current cash will not fund operations through September 2026. Negative working capital of $5.1 million.
-
Net Loss Widens
Net loss of $2.69 million for six months ended June 30, 2026, versus $1.32 million in the prior year period. Loss per share of $0.02.
-
CEO Performance Grant
Board awarded CEO David Platt 6,000,000 preferred shares (1:5 conversion) valued at $1.28 million as a performance grant, recorded as stock-based compensation.
-
Material Weakness
Disclosure controls and internal control over financial reporting were not effective due to a material weakness in segregation of duties.
Analysis · BIXT · Life Sciences
The Q2 2026 report from Bioxytran confirms the company has cash only through September 2026, a net loss of $2.69 million for the first half, and a material weakness in internal controls. The CEO received a $1.28 million performance grant in preferred shares, and a former officer's wage claim was assessed at $186,960.97. The company raised $23,000 in a subsequent private placement at a premium, but the going concern warning and cash runway dominate the risk profile.
At the time of this filing, BIXT was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.02 to $0.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.